breast cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: pathologically proven invasive breast cancer planned to receive 4 cycle of weekly paclitaxel treatment adequate hematologic, hepatic, and renal function Eastern Cooperative Oncology Group performance status of 0 to 1 providing written informed consent
Exclusion criteria
Exclusion criteria: peripheral neuropathy grade 2 or higher receiving any agents that altering peripheral neuropathy Raynaud's phenomenon pregnancy or breast feeding any other reason of no-suitable for registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FACT-NTX(Functional Assessment of Cancer Therapy-neurotoxicity) score | — |
Secondary
| Measure | Time frame |
|---|---|
| FACT-Taxane score, PNQ(Patient Neurotoxicity Questionnaire), CTCAE (common terminology criteria for adverse event) for periphereal neuropathy, safety, Evaluation of the temperature of the tip of each hand and foot | — |
Countries
Japan
Contacts
National hospital organization KURE medical center Breast surgery